Frontiers in endocrinology · 2025
Efficacy and safety of anlotinib combined with 125I seed implantation for iodine-refractory thyroid cancer.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Zhijun, Tang Xinlan, Tan Liling, Su Yu, Wang Wenjun, Wu Zhen
Аннотация
BACKGROUND AND OBJECTIVE: Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) remains challenging to treat due to a lack of effective therapies. This study aimed to evaluate the efficacy and safety of combining anlotinib with iodine-125 (125I) seed implantation in patients with RAIR-DTC.
METHODS AND MATERIALS: We retrospectively compared three treatment groups in 52 patients with advanced RAIR-DTC: anlotinib monotherapy (Group A, n = 14), 125I seed brachytherapy monotherapy (Group B, n = 25), and combined therapy (Group C, n = 13). Clinical outcomes including local progression-free survival (LPFS), overall survival (OS), tumor response, serum thyroglobulin (Tg) levels, and adverse events were analyzed.
RESULTS: As of February 2025, the combination therapy group achieved a longer median LPFS (42.2 months) than either monotherapy group (18.6-18.7 months; p = 0.023) and a higher objective response rate at 6 months (77% vs. 21-32% with monotherapies; p < 0.05). Tumor volumes in all groups decreased after treatment, with the greatest reduction within 6 months in the combination group (p < 0.001). By 12 months, response differences between groups narrowed, and median OS was similar across groups (~22-43 months, p = 0.425). Serum Tg levels declined significantly from baseline in all groups. No major procedural complications occurred, and treatment-related adverse reactions were mostly mild (Grade 1-2) and comparable among groups.
CONCLUSION: Combining 125I seed brachytherapy with anlotinib demonstrated superior short-term tumor control and prolonged local disease remission in RAIR-DTC, without increasing toxicity. This combination may offer a promising therapeutic option for RAIR-DTC, pending further validation in larger studies.
CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov, identifier NCT06362772.
METHODS AND MATERIALS: We retrospectively compared three treatment groups in 52 patients with advanced RAIR-DTC: anlotinib monotherapy (Group A, n = 14), 125I seed brachytherapy monotherapy (Group B, n = 25), and combined therapy (Group C, n = 13). Clinical outcomes including local progression-free survival (LPFS), overall survival (OS), tumor response, serum thyroglobulin (Tg) levels, and adverse events were analyzed.
RESULTS: As of February 2025, the combination therapy group achieved a longer median LPFS (42.2 months) than either monotherapy group (18.6-18.7 months; p = 0.023) and a higher objective response rate at 6 months (77% vs. 21-32% with monotherapies; p < 0.05). Tumor volumes in all groups decreased after treatment, with the greatest reduction within 6 months in the combination group (p < 0.001). By 12 months, response differences between groups narrowed, and median OS was similar across groups (~22-43 months, p = 0.425). Serum Tg levels declined significantly from baseline in all groups. No major procedural complications occurred, and treatment-related adverse reactions were mostly mild (Grade 1-2) and comparable among groups.
CONCLUSION: Combining 125I seed brachytherapy with anlotinib demonstrated superior short-term tumor control and prolonged local disease remission in RAIR-DTC, without increasing toxicity. This combination may offer a promising therapeutic option for RAIR-DTC, pending further validation in larger studies.
CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov, identifier NCT06362772.